Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan + Sintilimab in 2L Gastric Cancer
NCT06697366Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposome, sintilimab in gastric cancer (GC), sponsored by Ruijin Hospital. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
irinotecan liposomesintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06697366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697366.